Genoskin, a biotechnology company using live ex vivo human skin to test therapeutic and non-therapeutic products, has launched Mantis, a new spatial biology imaging platform dedicated to skin immunology. This new offer was developed by Genoskin’s recently appointed CSO Dr. Nicolas Gaudenzio and his team at Inserm. What is Mantis? … Read More
According to a new study, scientists have found chewing gum laced with a plant-grown protein serves as a “trap” for the SARS-CoV-2 virus, reducing viral load in saliva and potentially tamping down transmission. The study The work, led by Henry Daniell at the University of Pennsylvania’s School… Read More
In this free webinar, Dr. Christoph Herbel presents a newly developed workflow which combines flow cytometry–based screenings with high-parameter imaging to identify and validate new tumour markers in an unbiased approach. The event, Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy, was hosted by DDW and supported by Miltenyi Biotec. It… Read More
GlaxoSmithKline (GSK) and the University of Oxford have announced a five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine, which will be based at the University of Oxford and improve the success and speed of research and development of new medicines, building on insights from human… Read More
Biotheus, a biotechnology company based in Zhuhai, China, with multiple clinical-stage assets under clinical development, has announced that its anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the United States Food and Drug Administration (FDA) for conducting clinical Phase II studies as part of an international multicentre clinical trial. … Read More
Moderna has announced a revised supply agreement with the UK government for up to 60 million doses of its Covid-19 vaccine, which may include authorised booster vaccine candidates, with up to 29 million doses expected to be delivered in 2022 and up to 31 million doses expected to be delivered in 2023. Read More
Regulus Therapeutics, a biopharmaceutical company focused on the discovery and development of medicines targeting microRNAs, has appointed Mohammad Ahmadian as Vice President of Chemistry and Pharmaceutical Development. The role In his role, Dr. Ahmadian will assist in managing research and development of the company’s drug… Read More
MImAbs has acquired the Berkeley Lights Beacon system via a TechAccess subscription to help its customers in the generation and validation of novel therapeutic antibodies against cancer and inflammatory diseases. The acquisition This marks the first Beacon platform to be used in France, which enables MImAbs to provide research institutions,… Read More
Sixfold Bioscience (Sixfold), a company using computation and advanced chemistry to design RNA therapeutic delivery systems, has raised $10.5 million in its seed funding round, which will support the continued development of the company’s Mergo RNA therapeutics delivery platform. Investors Investors in the seed round included Cantos Ventures, Y Combinator, Lombard Street… Read More
News round-up by DDW’s Megan Thomas for 29 November – 3 December DDW’s Megan Thomas has rounded up five stories this week that showcase the different ways in which breakthroughs, agreements, trials and research developments influence the drug discovery world. 1. Agreement to develop… Read More
Since South African scientists successfully sequenced the Omicron variant on November 19, the variant – also known as B.1.1.529 – has now been identified internationally. Tracking cases and speeding up booster jabs is critical, but a survey by Solace of 840 IT professionals revealed that only 17% of life… Read More
Following the approval of GlaxoSmithKline (GSK) and Vir Biotechnology’s Covid-19 drug Xevudy (sotrovimab), the companies have announced an update, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. … Read More
Infex Therapeutics scientists have announced a breakthrough in laboratory trials of a new drug to treat Covid-19 and new variants of the disease, such as the Omicron variant. Infex’s COV-X programme inhibits a new protease target that is responsible for viral replication across the broad spectrum of SARS-CoV-1, MERS-CoV and SARS-CoV-2. As such,… Read More
The Medicines and Healthcare products Regulatory Agency (MHRA), in the UK, has approved GSK and Vir Biotechnology’s Covid-19 drug Xevudy (sotrovimab), after it was found to be safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate Covid-19 infection who are at an increased risk of developing severe… Read More
Dr. Ken Ng, a professor at the University of Windsor and adjunct professor at the University of Calgary (UCalgary), and Sam Carr, a PhD student from UCalgary, have been working with Dr. Peter Facchini’s group at UCalgary to better understand how natural opiates are produced. The team has narrowed their focus on one… Read More
Formedix, a provider of clinical trial software solutions, has launched the Formedix ryze Community to provide customers with a location to collaborate, expand their knowledge and share information. What does the platform do? Through a range of tools, the ryze Community will support the pharmaceutical industry to streamline and enhance… Read More
